Compare

Natera vs Agilent Technologies

MonkScore ranges and fundamentals, side by side

Key facts

Natera and Agilent Technologies: key facts

  • In fiscal 2025, Natera, Inc. reported revenue of $2.3B and net income of -$208.2M.
  • In fiscal 2025, Agilent Technologies, Inc. reported revenue of $6.9B and net income of $1.3B.
  • Natera, Inc.'s revenue grew 38.6% a year from fiscal 2021 to fiscal 2025.
  • Agilent Technologies, Inc.'s revenue grew 2.4% a year from fiscal 2021 to fiscal 2025.
  • Natera, Inc.'s free cash flow was positive in 2 of the 5 fiscal years from 2021 to 2025.
  • Agilent Technologies, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 June 2026, Natera, Inc. reported revenue of $2.7B and net income of -$192.3M.
  • In the twelve months to 31 July 2026, Agilent Technologies, Inc. reported revenue of $7.4B and net income of $1.4B.

Side by side

Natera and Agilent Technologies, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureNatera, Inc.NASDAQ:NTRAAgilent Technologies, Inc.NYSE:A
MonkScore
MonkScore range70–80as of October 202670–80as of October 2026
Sector rank208 of 628 in Healthcare146 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Latest fiscal year
Revenue$2.3BFY 2025$6.9BFY 2025
Net income-$208.2MFY 2025$1.3BFY 2025
Free cash flow$109.1MFY 2025$1.2BFY 2025
Operating cash flow$215.3MFY 2025$1.6BFY 2025
Total debt$214.4MFY 2025$3.4BFY 2025
Cash$1.1BFY 2025$1.8BFY 2025
Last 12 months
Revenue$2.7Bto 30 June 2026$7.4Bto 31 July 2026
Net income-$192.3Mto 30 June 2026$1.4Bto 31 July 2026
Free cash flow$71.7Mto 30 June 2026$1.4Bto 31 July 2026
Operating cash flow$228.2Mto 30 June 2026$1.6Bto 31 July 2026
Total debt$238.5Mto 30 June 2026$3.9Bto 31 July 2026
Cash$1.1Bto 30 June 2026$1.8Bto 31 July 2026

MonkStreet provides research, not investment advice.